Unlocking the power of the immune system against cancer and autoimmune disease.

A Global Leader in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Our LAG-3 immunotherapies are distinctly designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.

Latest press releases.

May 26th 2025

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15th 2025

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
May 5th 2025

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
more

About us.

our science.

Utilizing our LAG-3 expertise, we’re focused on safely delivering on immunotherapy’s promise to drive superior clinical outcomes for patients.

our pipeline.

We have four clinical-stage assets & one earlier stage candidate, reflecting our unique ability to harness the LAG-3 immune checkpoint to stimulate or suppress the immune system.

investors & media.

We are dedicated to leveraging our technology to develop innovative treatment options for patients and to maximise value to shareholders. Learn more.